PMC:7228307 / 4118-4529 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"48","span":{"begin":353,"end":357},"obj":"Gene"},{"id":"49","span":{"begin":141,"end":145},"obj":"Gene"}],"attributes":[{"id":"A48","pred":"tao:has_database_id","subj":"48","obj":"Gene:2213"},{"id":"A49","pred":"tao:has_database_id","subj":"49","obj":"Gene:2213"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"s—which leads to the destruction of opsonized pathogens—and of the modulation of these destructive effector responses by the inhibitory‐type FcγR, thereby avoiding injury to the host. Thus, therapeutic mAbs powerfully exploit these opposing activities, making them versatile drugs whose therapeutic potency can be improved by specific engineering of Fc–FcγR interactions.7\nMany therapeutic mAbs depend, to varyi"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T13","span":{"begin":164,"end":170},"obj":"Disease"}],"attributes":[{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"}],"text":"s—which leads to the destruction of opsonized pathogens—and of the modulation of these destructive effector responses by the inhibitory‐type FcγR, thereby avoiding injury to the host. Thus, therapeutic mAbs powerfully exploit these opposing activities, making them versatile drugs whose therapeutic potency can be improved by specific engineering of Fc–FcγR interactions.7\nMany therapeutic mAbs depend, to varyi"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T46","span":{"begin":141,"end":143},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T47","span":{"begin":241,"end":251},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T48","span":{"begin":350,"end":352},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T49","span":{"begin":353,"end":355},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"}],"text":"s—which leads to the destruction of opsonized pathogens—and of the modulation of these destructive effector responses by the inhibitory‐type FcγR, thereby avoiding injury to the host. Thus, therapeutic mAbs powerfully exploit these opposing activities, making them versatile drugs whose therapeutic potency can be improved by specific engineering of Fc–FcγR interactions.7\nMany therapeutic mAbs depend, to varyi"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T12","span":{"begin":99,"end":107},"obj":"Chemical"},{"id":"T13","span":{"begin":275,"end":280},"obj":"Chemical"}],"attributes":[{"id":"A12","pred":"chebi_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_35224"},{"id":"A13","pred":"chebi_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"s—which leads to the destruction of opsonized pathogens—and of the modulation of these destructive effector responses by the inhibitory‐type FcγR, thereby avoiding injury to the host. Thus, therapeutic mAbs powerfully exploit these opposing activities, making them versatile drugs whose therapeutic potency can be improved by specific engineering of Fc–FcγR interactions.7\nMany therapeutic mAbs depend, to varyi"}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T20","span":{"begin":46,"end":55},"obj":"http://purl.obolibrary.org/obo/IDO_0000528"},{"id":"T21","span":{"begin":178,"end":182},"obj":"http://purl.obolibrary.org/obo/IDO_0000531"}],"text":"s—which leads to the destruction of opsonized pathogens—and of the modulation of these destructive effector responses by the inhibitory‐type FcγR, thereby avoiding injury to the host. Thus, therapeutic mAbs powerfully exploit these opposing activities, making them versatile drugs whose therapeutic potency can be improved by specific engineering of Fc–FcγR interactions.7\nMany therapeutic mAbs depend, to varyi"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"48","span":{"begin":353,"end":357},"obj":"Gene"},{"id":"49","span":{"begin":141,"end":145},"obj":"Gene"}],"attributes":[{"id":"A48","pred":"pubann:denotes","subj":"48","obj":"Gene:2213"},{"id":"A49","pred":"pubann:denotes","subj":"49","obj":"Gene:2213"}],"text":"s—which leads to the destruction of opsonized pathogens—and of the modulation of these destructive effector responses by the inhibitory‐type FcγR, thereby avoiding injury to the host. Thus, therapeutic mAbs powerfully exploit these opposing activities, making them versatile drugs whose therapeutic potency can be improved by specific engineering of Fc–FcγR interactions.7\nMany therapeutic mAbs depend, to varyi"}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T24","span":{"begin":184,"end":372},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"s—which leads to the destruction of opsonized pathogens—and of the modulation of these destructive effector responses by the inhibitory‐type FcγR, thereby avoiding injury to the host. Thus, therapeutic mAbs powerfully exploit these opposing activities, making them versatile drugs whose therapeutic potency can be improved by specific engineering of Fc–FcγR interactions.7\nMany therapeutic mAbs depend, to varyi"}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T10","span":{"begin":164,"end":170},"obj":"Disease"}],"attributes":[{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"}],"text":"s—which leads to the destruction of opsonized pathogens—and of the modulation of these destructive effector responses by the inhibitory‐type FcγR, thereby avoiding injury to the host. Thus, therapeutic mAbs powerfully exploit these opposing activities, making them versatile drugs whose therapeutic potency can be improved by specific engineering of Fc–FcγR interactions.7\nMany therapeutic mAbs depend, to varyi"}

{"project":"LitCovid-sentences","denotations":[{"id":"T24","span":{"begin":184,"end":372},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"s—which leads to the destruction of opsonized pathogens—and of the modulation of these destructive effector responses by the inhibitory‐type FcγR, thereby avoiding injury to the host. Thus, therapeutic mAbs powerfully exploit these opposing activities, making them versatile drugs whose therapeutic potency can be improved by specific engineering of Fc–FcγR interactions.7\nMany therapeutic mAbs depend, to varyi"}